Abstract
Retroviruses carry cell-derived oncogenes (v-onc) that have the potential to transform cells in culture and induce tumours in vivo1,2. One of the few carcinoma-inducing viruses is the acutely transforming retrovirus MH2 (refs 2,3), which carries the putative oncogene v-mil and the known oncogene v-myc(refs 4–6). Recently, a high degree of homology was discovered between v-mil and v-raf (ref. 7), the transforming gene of the murine retrovirus 3611 murine sarcoma virus (MSV)8, whereas homology to v-src is low9. Both viruses express their oncogenes as the gag-fusion polyproteins6,10 p100gag-mil and p75gag-raf (of respective relative molecular mass (Mr) 100,000 and 75,000), while the myc oncogene of MH2 is expressed by means of a subgenomic messenger RNA11. We have recently demonstrated that p100gag-mil is not a nuclear protein6. Here we report that purified p100gag-mil and p75gag-raf exhibit protein kinase activities in vitro which, in contrast to the src-related p130gag-fps of Fujinami sarcoma virus (FSV)12 and all other characterized oncogene-encoded protein kinases, phosphorylate serine and threonine but not tyrosine. Both types of protein kinases phosphorylate lipids in vitro.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Bishop, J. M. A. Rev. Biochem. 52, 301–354 (1983).
Beard, J. W. in Viral Oncology (ed. Klein, G.) 55–87 (Raven, New York, 1980).
Alexander, R. W., Moscovici, C. & Vogt, P. K. J. natn. Cancer Inst. 62, 359–366 (1979).
Jansen, H. W., Patschinsky, T. & Bister, K. J. Virol. 48, 61–73 (1983).
Kan, N. C. et al. Proc. natn. Acad. Sci. U.S.A. 80, 6566–6570 (1983).
Bunte, T., Greiser-Wilke, I. & Moelling, K. EMBO J. 2, 1087–1092 (1983).
Jansen, H. W. et al. Nature 307, 281–284 (1984).
Rapp, U. R. Proc. natn. Acad. Sci. U.S.A. 80, 4218–4222 (1983).
Sutrave, P. et al. Nature 309, 85–88 (1984).
Rapp, U. R., Reynolds, F. H. & Stephenson, J. R. J. Virol. 45, 914–924 (1983).
Pachl, C., Biegalke, B. & Linial, M. J. Virol. 45, 133–139 (1983).
Feldman, R. A., Hanafusa, T. & Hanafusa, H. Cell 22, 757–765 (1980).
Moelling, K. Adv. Cancer Res. 43 (in the press).
Moelling, K., Owada, M. K., Greiser-Wilke, I., Bunte, T. & Donner, P. J. cell. Biochem. 20, 63–69 (1982).
Moelling, K., Bunte, T., Greiser-Wilke, I., Donner, P. & Pfaff, H. in Cancer Cells Vol. 2, 173–180 (Cold Spring Harbor Laboratory, New York, 1984).
Moelling, K., Donner, P., Bunte, T. & Greiser-Wilke, I. Contr. Oncol. 19, 35–43 (1984).
Donner, P., Greiser-Wilke, I. & Moelling, K. Nature 296, 262–266 (1982).
Sefton, B. M., Hunter, T., Beemon, K. & Eckardt, W. Cell 20, 807–816 (1980).
Mark, G. E. & Rapp, U. R. Science 224, 285–289 (1984).
Sugimoto, Y., Whitman, M., Cantley, L. C. & Erikson, R. L. Proc. natn. Acad. Sci. U.S.A. 81, 2117–2121 (1984).
Macara, I. G., Marinetti, G. V. & Balduzzi, P. C. Proc. natn. Acad. Sci. U.S.A. 81, 2728–2732 (1984).
Kloetzer, W. S., Maxwell, S. A. & Arlinghaus, R. B. Proc. natn. Acad. Sci. U.S.A. 80, 412–416 (1983).
Moelling, K., Sykora, K.-W., Dittmar, K., Scott, A. & Watson, K. F. J. biol. Chem. 254, 3738–3742 (1979).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Moelling, K., Heimann, B., Beimling, P. et al. Serine- and threonine-specific protein kinase activities of purified gag–mil and gag–raf proteins. Nature 312, 558–561 (1984). https://doi.org/10.1038/312558a0
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/312558a0
This article is cited by
-
Anoikis resistance––protagonists of breast cancer cells survive and metastasize after ECM detachment
Cell Communication and Signaling (2023)
-
Targeting the RAS/RAF/MAPK pathway for cancer therapy: from mechanism to clinical studies
Signal Transduction and Targeted Therapy (2023)
-
The MAPK and AMPK signalings: interplay and implication in targeted cancer therapy
Journal of Hematology & Oncology (2020)
-
Clinical development of targeted and immune based anti-cancer therapies
Journal of Experimental & Clinical Cancer Research (2019)
-
Targeting CDC7 sensitizes resistance melanoma cells to BRAFV600E-specific inhibitor by blocking the CDC7/MCM2-7 pathway
Scientific Reports (2019)
Comments
By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.